Sinonasal NUT Carcinoma: A Consecutive Case Series and Systematic Review
Overview
Authors
Affiliations
Background: Sinonasal NUT carcinoma is an extremely rare, lethal malignancy with limited literature.
Methods: A case series was conduction of all patients with sinonasal NUT carcinoma at a single institution between 2010 and 2022. Survival and associated were evaluated. A systematic review of the literature was performed.
Results: In 12 patients, followed for a median of 1.5 years, the median overall survival (OS) and disease-specific survival (DSS) were both 14.6 months. Patients with maxillary sinus tumors were 91% more likely to survive (hazard ratio [HR]: 0.094, 95% confidence interval [CI]: 0.011-0.78, p = 0.011). Patients with higher-stage disease stage had worse OS (stage IVb-c vs. III-IVa, p = 0.05). All three patients who were alive with no evidence of disease received induction chemotherapy.
Conclusion: For patients with sinonasal NUT carcinoma, the median survival was 15 months but better with lower-stage and maxillary tumors. Induction chemotherapy may be beneficial.
Ng J, Wong E, So T, Wong R Front Oncol. 2025; 14():1412070.
PMID: 39839761 PMC: 11746124. DOI: 10.3389/fonc.2024.1412070.
Geng X, Chang X, Wang X, Li S, Han G, Song Z Front Oncol. 2024; 14:1368187.
PMID: 39711966 PMC: 11659667. DOI: 10.3389/fonc.2024.1368187.
[Research Progress on Pathogenesis and Treatment of NUT Carcinoma].
Du J, Zhang X Zhongguo Fei Ai Za Zhi. 2024; 27(6):466-470.
PMID: 39026498 PMC: 11258642. DOI: 10.3779/j.issn.1009-3419.2024.101.16.
Viswanathan K, Hahn E, Dogan S, Weinreb I, Dickson B, MacMillan C Histopathology. 2024; 85(2):317-326.
PMID: 38708903 PMC: 11246813. DOI: 10.1111/his.15204.
Skalova A, Agaimy A, Bradova M, Vander Poorten V, Hanna E, Guntinas-Lichius O Virchows Arch. 2024; 484(6):885-900.
PMID: 38491228 PMC: 11186917. DOI: 10.1007/s00428-024-03775-y.